Traders assign a strong 91% probability to no new COVID variant of concern before 2027 because current SARS-CoV-2 evolution shows limited public health impact despite ongoing mutations. Established immunity from prior infections, vaccinations, and updated 2026-2027 formulas targeting lineages like XFG and JN.1 descendants continues to limit severity. Health agencies such as WHO and ECDC report no variants meeting VOC criteria as of mid-2026, with strains like BA.3.2 (Cicada) and NB.1.8.1 classified only as variants under monitoring or interest due to low additional risk of hospitalization or mortality. Genomic surveillance confirms stable circulation patterns without the transmissibility or immune-escape jumps needed to trigger reclassification, supporting the market's consensus on the near-term outlook.